About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker GILD · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026Study of GS-2426 in Participants With Advanced Solid Tumors
NCT07601243 · Advanced Solid Tumors
GS-2426
GILD
Gilead Sciences
Phase 1Recruiting174Jan 2029Registry ↗
Nov 12, 2026Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
NCT06167317 · Advanced Solid Tumors
GS-0201, Sacituzumab Govitecan
GILD
Gilead Sciences
Phase 1Recruiting278Sep 2028Registry ↗
Nov 12, 2026Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory La…
NCT05459571 · Relapsed or Refractory Large B-cell Lymphoma
Axicabtagene Ciloleucel, Cyclophosphamide
GILD
Kite, A Gilead Company
Phase 2Completed35Nov 24, 2025Registry ↗
Nov 12, 2026Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Vir…
NCT02932150 · Chronic Hepatitis B
TAF, Placebo
GILD
Gilead Sciences
Phase 2Active, not recruiting150Oct 27, 2026Registry ↗
Nov 10, 2026Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HI…
NCT07708727 · HIV-1-infection
GS-3242 Tablet, GS-3242 Injection
GILD
Gilead Sciences
Phase 2/3Recruiting700Oct 2030Registry ↗
Nov 10, 2026A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed Peop…
NCT07645287 · HIV-1-infection
GS-3242 Tablet, GS-3242 Injection
GILD
Gilead Sciences
Phase 2Recruiting175Aug 2027Registry ↗
Nov 10, 2026Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastati…
NCT07546812 · HER2-negative, Gastroesophageal Junction
Denikitug, Nivolumab
GILD
Gilead Sciences
Phase 2Active, not recruiting
was recruiting
120Jan 2030Registry ↗
Nov 6, 2026A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Cl…
NCT06337032 · HIV-1-infection
F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet)
GILD
Gilead Sciences
Phase 4Recruiting350Jun 2027Registry ↗
Nov 5, 2026Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Succes…
NCT06333808 · HIV-1-infection
Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir
GILD
Gilead Sciences
Phase 3Active, not recruiting577Oct 27, 2025Registry ↗
Nov 5, 2026Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Succes…
NCT05502341 · HIV-1-infection
Bictegravir, Lenacapavir
GILD
Gilead Sciences
Phase 2/3Active, not recruiting689Sep 29, 2025Registry ↗
Nov 4, 2026A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors
NCT07703878 · Solid Tumor
GS-1206
GILD
Gilead Sciences
Phase 1Recruiting302Sep 2029Registry ↗
Nov 4, 2026Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Pat…
NCT05633654 · Triple Negative Breast Cancer
Sacituzumab govitecan-hziy (SG), Pembrolizumab
GILD
Gilead Sciences
Phase 3Recruiting1,514Jun 2027Registry ↗
Nov 3, 2026Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Geni…
NCT07912996 · HSV-2 Infection
GS-1179, GS-1179 PTM
GILD
Gilead Sciences
Phase 2Not yet recruiting300Nov 2027Registry ↗
Nov 3, 2026FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or…
NCT06303505 · Ovarian Cancer, Non-small Cell Lung Cancer
TUB-040, Bevacizumab
GILD
Gilead Sciences
Phase 1/2Recruiting334Dec 2027Registry ↗
Nov 2, 2026Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV
NCT07908446 · HIV-1 Infection
BIC/LEN FDC, Lenacapavir
GILD
Gilead Sciences
Phase 4Not yet recruiting400Jul 2028Registry ↗
Nov 2, 2026Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617 · Primary Biliary Cholangitis
Seladelpar, Placebo
GILD
Gilead Sciences
Phase 3Recruiting402Aug 2030Registry ↗
Nov 2, 2026Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucab…
NCT05776134 · Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia
Brexucabtagene Autoleucel
GILD
Kite, A Gilead Company
—Available——Registry ↗
Oct 29, 2026To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant…
NCT07903506 · Newly Diagnosed Multiple Myeloma
Anitocabtagene Autoleucel, Isatuximab
GILD
Kite, A Gilead Company
Phase 3Not yet recruiting750Mar 2039Registry ↗
Oct 28, 2026Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
NCT04989803 · Relapsed and/or Refractory B-cell Lymphoma
Cyclophosphamide, Fludarabine
GILD
Kite, A Gilead Company
Phase 1/2Active, not recruiting247Feb 2030Registry ↗
Oct 27, 2026Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis
NCT07841977 · Primary Biliary Cholangitis
Seladelpar, PTM Seladelpar
GILD
Gilead Sciences
Phase 2Recruiting132Dec 2028Registry ↗
Oct 26, 2026Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relap…
NCT07479797 · Relapsed or Refractory Large B-cell Lymphoma
KITE-753, Axicabtagene Ciloleucel
GILD
Kite, A Gilead Company
Phase 3Active, not recruiting550May 2031Registry ↗
Oct 23, 2026Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undet…
NCT07841990 · HIV-1 Infection
B/F/TAF, GS-3242
GILD
Gilead Sciences
Phase 2Recruiting125Aug 2027Registry ↗
Oct 23, 2026Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors
NCT07128303 · Advanced Solid Tumor
GS-5319, Carboplatin
GILD
Gilead Sciences
Phase 1Recruiting476May 2028Registry ↗
Oct 22, 2026Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
NCT06626919 · Muscular Diseases, Neuromuscular Manifestations
anito-cel, Cyclophosphamide
GILD
Kite, A Gilead Company
Phase 1Recruiting30Oct 2028Registry ↗
Oct 22, 2026Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometr…
NCT06486441 · Endometrial Cancer
Sacituzumab govitecan-hziy, Doxorubicin
GILD
Gilead Sciences
Phase 3Active, not recruiting640Jun 2029Registry ↗
Oct 21, 2026A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in New…
NCT07887672 · Newly Diagnosed Multiple Myeloma
Anitocabtagene autoleucel, Daratumumab
GILD
Kite, A Gilead Company
Phase 3Not yet recruiting600Feb 2042Registry ↗
Oct 21, 2026Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
NCT07473778 · HIV Infections
Lenacapavir Injection, Emtricitabine/tenofovir disoproxil f…
GILD
Gilead Sciences
—Recruiting3,000Apr 2028Registry ↗
Oct 20, 2026Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Adva…
NCT07527858 · Advanced Microsatellite Stable Colorectal Cancer
Denikitug, Nivolumab
GILD
Gilead Sciences
Phase 2Recruiting170Dec 2028Registry ↗
Oct 20, 2026Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Exte…
NCT06801834 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sacituzumab Govitecan (SG), Topotecan
GILD
Gilead Sciences
Phase 3Recruiting695Oct 2029Registry ↗
Oct 19, 2026Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual…
NCT07304154 · Chronic Inflammatory Demyelinating Polyneuropathy, Myasthen…
KITE-363, Fludarabine
GILD
Kite, A Gilead Company
Phase 1Recruiting57Jun 2029Registry ↗
Oct 16, 2026Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent…
NCT04994509 · Pre-Exposure Prophylaxis of HIV Infection
Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN)
GILD
Gilead Sciences
Phase 3Active, not recruiting5,368May 27, 2024Registry ↗
Oct 6, 2026Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants…
NCT06562907 · Weight Management
GS-4571, Placebo
GILD
Gilead Sciences
Phase 1Recruiting134Feb 2027Registry ↗
Oct 6, 2026Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men,…
NCT04925752 · Pre-Exposure Prophylaxis of HIV Infection
Oral Lenacapavir (LEN), F/TDF
GILD
Gilead Sciences
Phase 3Active, not recruiting3,292Aug 21, 2024Registry ↗
Oct 2, 2026Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leu…
NCT05457010 · Acute Myeloid Leukemia, Myelodysplastic Syndromes
SPRX002, ARC-T Cells
GILD
Kite, A Gilead Company
Phase 1Active, not recruiting24Oct 2026Registry ↗
Oct 1, 2026Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized…
NCT04150068 · HIV-1-infection
Oral Lenacapavir, Oral Lenacapavir Placebo
GILD
Gilead Sciences
Phase 2/3Active, not recruiting72Oct 5, 2020Registry ↗
Sep 29, 2026Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
NCT06532656 · HIV-1-infection
Lenacapavir, Bictegravir/Lenacapavir (BIC/LEN) FDC
GILD
Gilead Sciences
Phase 2/3Active, not recruiting75Jul 2030Registry ↗
Sep 28, 2026A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
NCT07038447 · Systemic Lupus Erythematosus, Lupus Nephritis
KITE-363, Fludarabine
GILD
Kite, A Gilead Company
Phase 1Enrolling by invitation52Sep 2030Registry ↗
Sep 24, 2026Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and…
NCT02881320 · HIV-1 Infection
B/F/TAF (Adult Strength), B/F/TAF (Low Dose)
GILD
Gilead Sciences
Phase 2/3Active, not recruiting177Mar 24, 2025Registry ↗
Sep 23, 2026Study of GS-0415 and How It Works in People With HIV
NCT07719491 · HIV -1 Infection
GS-0415, GS-0415 Placebo
GILD
Gilead Sciences
Phase 1Recruiting112Aug 2029Registry ↗
Sep 21, 2026Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
NCT05041309 · Solid and Hematological Malignancies, Autoimmune Diseases
Axicabtagene Ciloleucel, Brexucabtagene Autoleucel
GILD
Kite, A Gilead Company
—Enrolling by invitation1,500Dec 2040Registry ↗
Sep 18, 2026Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
NCT05718700 · Chronic Hepatitis D Infection
Bulevirtide
GILD
Gilead Sciences
—Terminated170Aug 31, 2026Registry ↗
Sep 18, 2026Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in…
NCT02252835 · Gout, Hyperuricemia
Arhalofenate, Febuxostat
GILD
Gilead Sciences
Phase 2Completed32Dec 2014Registry ↗
Sep 18, 2026Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
NCT01336686 · Hyperuricemia, Gout
Arhalofenate, Arhalofenate
GILD
Gilead Sciences
Phase 2Completed67Nov 2011Registry ↗
Sep 18, 2026Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered…
NCT01035879 · Diabetes
MBX-2982, MBX-2982
GILD
Gilead Sciences
Phase 2Completed100Aug 2010Registry ↗
Sep 18, 2026Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control…
NCT00814372 · Type 2 Diabetes Mellitus
MBX-102, Placebo
GILD
Gilead Sciences
Phase 2Terminated242Feb 2010Registry ↗
Sep 17, 2026Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
NCT05007782 · Advanced Solid Tumor
Denikitug, Zimberelimab
GILD
Gilead Sciences
Phase 1Active, not recruiting304Dec 2028Registry ↗
Sep 16, 2026Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Ca…
NCT07806773 · NSCLC, Non Small Cell Lung Cancer
TUB-040
GILD
Gilead Sciences
Phase 2Not yet recruiting80May 2029Registry ↗
Sep 11, 2026First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222 · Advanced Solid Tumors, HNSCC
TUB-030
GILD
Gilead Sciences
Phase 1/2Recruiting250Dec 2028Registry ↗
Sep 11, 2026Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Coli…
NCT06029972 · Ulcerative Colitis
Tilpisertib Fosmecarbil, Placebo
GILD
Gilead Sciences
Phase 2Active, not recruiting176Jan 2027Registry ↗
Sep 11, 2026Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced o…
NCT05186974 · Non-small Cell Lung Cancer
Sacituzumab Govitecan-hziy (SG), Pembrolizumab
GILD
Gilead Sciences
Phase 2Active, not recruiting193Mar 2027Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:53 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances